STAT

Pharma is making progress addressing global health, but it’s still a mixed bag

Drug makers are taking steps to reach people on very low incomes, but access programs are for just a few diseases.
Source: APStock

As the pharmaceutical industry confronts growing demands to improve global health and combat neglected diseases, a new analysis finds patchy progress as most efforts are undertaken by a handful of companies targeting only a few maladies in a small number of low and middle-income countries.

Drug makers taking steps to reach people on very low incomes and R&D pipelines have grown, but patient access programs have been confined to just a few diseases, only some companies are tackling the risks of unethical sales behavior, and still fewer support.

You're reading a preview, sign up to read more.

More from STAT

STAT3 min readPsychology
Opinion: In A Medical Emergency, Who In Your Social Network Will Call For Help Quickest?
Applying the "strength of weak ties" theory to medicine, a weakly connected familiar in your social network can be the outside voice of reason who isn't afraid to call for…
STAT3 min read
Why Are Elite Athletes Different Than The Rest Of Us? Take A Look At Their Microbes
Elite athletes really are different from you and me. Or, at least their gut microbes are. Scientists who analyzed stool samples of 15 runners a week before and after they competed in the 2015 Boston Marathon found unusually high levels of one particu
STAT2 min read
How The Kaiser-Johns Hopkins Analysis Was Done
Kaiser Health News' analysis of surgeons’ prescribing habits was done in collaboration with researchers at Johns Hopkins School of Public Health.